Aprea Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aprea, a $8.6M market-cap oncology company, reported Q3 2026 cash of $37.8M (up from $14.6M at year-end 2025), funded by a $30M private placement closed March 31, 2026. The company expanded its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 from 3 to 9 clinical sites, targeting 6–10 patient enrollments per month in Q4 2026. Early data (n=28, cutoff May 6, 2026) showed 2 partial responses and 6 stable disease cases; company expects cash runway into Q1 2028 and will present updated interim results at EORTC-NCI-AACR Symposium November 20, 2026.
Why this rating
Significant fundraising ($30M ≈ 3.5x current market value) materially extends runway and funds trial expansion. Early clinical signals (PRs observed) and site acceleration support lead program viability relative to company size.
Tradability signal
NO TRADE
No trade: only ~$23k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.53 | +10 min · unknown $0.52 ▼ 1.70% | +30 min · unknown $0.52 ▼ 1.70% | +1 hr · unknown $0.53 ▲ 0.57% | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.